Last reviewed · How we verify
Nebulized heparin and salbutamol
Nebulized heparin and salbutamol work together to reduce airway inflammation and prevent thrombosis while bronchodilating the airways.
Nebulized heparin and salbutamol work together to reduce airway inflammation and prevent thrombosis while bronchodilating the airways. Used for Cystic fibrosis with airway inflammation, Chronic obstructive pulmonary disease with inflammatory component.
At a glance
| Generic name | Nebulized heparin and salbutamol |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Combination therapy: anticoagulant + bronchodilator |
| Target | Heparin: Factor IIa and Factor Xa; Salbutamol: Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonary |
| Phase | FDA-approved |
Mechanism of action
Heparin is an anticoagulant that also possesses anti-inflammatory properties when inhaled, helping to reduce airway inflammation and mucus production. Salbutamol is a beta-2 agonist bronchodilator that relaxes airway smooth muscle and improves airflow. The combination is used to manage respiratory conditions characterized by both airway obstruction and inflammatory/thrombotic components.
Approved indications
- Acute exacerbation of chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis with airway inflammation
- Acute asthma exacerbation with inflammatory component
Common side effects
- Tremor
- Tachycardia
- Headache
- Throat irritation
- Bleeding risk (minor)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebulized heparin and salbutamol CI brief — competitive landscape report
- Nebulized heparin and salbutamol updates RSS · CI watch RSS
- Ain Shams University portfolio CI